Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA: 600329)

Market Cap	22.55B
Revenue (ttm)	8.04B
Net Income (ttm)	932.37M
Shares Out	770.16M
EPS (ttm)	1.21
PE Ratio	28.02
Forward PE	22.98
Dividend	1.28 (3.80%)
Ex-Dividend Date	Jul 12, 2024

Volume	4,003,700
Open	33.51
Previous Close	33.65
Day's Range	33.50 - 34.40
52-Week Range	23.40 - 39.05
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Tianjin Pharmaceutical Da Ren Tang Group Corporation

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongji...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2023, Tianjin Pharmaceutical Da Ren Tang Group Corporation's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.